Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT03112681 Org: User:
Start: 08/18/17 End: 08/07/20 Due: 08/07/21

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

Phase: N/A Priority: Normal
NCT ID: NCT03863574 Org: User:
Start: 06/12/19 End: 03/20/20 Due: 03/20/21

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT07023835 Org: User:
Start: 09/30/25 End: 10/31/28 Due: 10/31/29

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT06825559 Org: User:
Start: 05/31/25 End: 08/31/25 Due: 08/31/26

Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT05045482 Org: User:
Start: 10/21/21 End: 06/30/25 Due: 06/30/26

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT05133336 Org: User:
Start: 04/01/22 End: 05/07/25 Due: 05/07/26

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

Phase: N/A Priority: Normal
NCT ID: NCT05211284 Org: User:
Start: 12/08/22 End: 10/02/23 Due: 10/02/24

Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04112446 Org: User:
Start: 09/20/19 End: 10/29/19 Due: 10/29/20

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Phase: N/A Priority: Normal
NCT ID: NCT03097107 Org: User:
Start: 04/06/17 End: 01/31/24 Due: 01/31/25

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT06427395 Org: User:
Start: 07/16/24 End: 07/18/27 Due: 07/18/28

Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)

Phase: N/A Priority: Normal
NCT ID: NCT03617263 Org: User:
Start: 02/12/19 End: 10/28/24 Due: 10/28/25

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04045769 Org: User:
Start: 08/19/19 End: 12/02/19 Due: 12/02/20

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT04469920 Org: User:
Start: 07/16/20 End: 03/21/22 Due: 03/21/23

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

Phase: N/A Priority: Normal
NCT ID: NCT03639623 Org: User:
Start: 02/25/19 End: 12/13/21 Due: 12/13/22

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05011305 Org: User:
Start: 08/18/21 End: 09/30/25 Due: 09/30/26

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT04446507 Org: User:
Start: 07/27/20 End: 05/28/24 Due: 05/28/25

Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Phase: N/A Priority: Normal
NCT ID: NCT03061721 Org: User:
Start: 04/06/17 End: 08/22/19 Due: 08/22/20